Li H, Walsh T N, Hennessy T P
University Department of Surgery, Trinity College Medical School, St. James's Hospital, Dublin, Ireland.
Surg Gynecol Obstet. 1992 Aug;175(2):167-72.
During the period 1971 and 1990, 500 patients underwent resection for carcinoma of the esophagus, 51 of whom had an associated Barrett's esophagus. Of these, 49 had adenocarcinoma and two had squamous cell carcinoma. Barrett's carcinoma accounted for 23.7 percent of the surgically treated adenocarcinomas during this period. Reflux symptoms were present in 13 patients preoperatively. Tumors developed in four patients who had undergone previous antireflux operation and in two patients on the surveillance program. By postresection staging, 18 patients had stage II tumors and 33 patients had stages III and IV tumors. Stage and length of the tumor were the only prognostic determinants. The overall 90 day hospital mortality rate was 17.6 percent. The hospital mortality rate before 1986 was 22.9 percent, but decreased to 6.3 percent in the last five years. The one, two and five year survival rates were 45.9, 25.0 and 13.6 percent, respectively. The five year survival rate was significantly greater for patients with stage II (25 percent) than for patients with stages III and IV (4.5 percent) (p less than 0.05) and for tumor length less than 6 centimeters (21 percent) than for tumors greater than 6 centimeters (zero percent; p less than 0.001).
在1971年至1990年期间,500例患者接受了食管癌切除术,其中51例伴有巴雷特食管。在这些患者中,49例为腺癌,2例为鳞状细胞癌。在此期间,巴雷特癌占手术治疗腺癌的23.7%。13例患者术前有反流症状。4例曾接受抗反流手术的患者和2例接受监测计划的患者发生了肿瘤。根据切除术后分期,18例患者为II期肿瘤,33例患者为III期和IV期肿瘤。肿瘤分期和长度是唯一的预后决定因素。90天总体医院死亡率为17.6%。1986年前医院死亡率为22.9%,但在最后五年降至6.3%。1年、2年和5年生存率分别为45.9%、25.0%和13.6%。II期患者(25%)的5年生存率显著高于III期和IV期患者(4.5%)(p<0.05),肿瘤长度小于6厘米的患者(21%)的5年生存率显著高于肿瘤长度大于6厘米的患者(0%;p<0.001)。